Increased Bone Mass in Female Mice Lacking Mast Cell Chymase

Here we addressed the potential impact of chymase, a mast-cell restricted protease, on mouse bone phenotype. We show that female mice lacking the chymase Mcpt4 acquired a persistent expansion of diaphyseal bone in comparison with wild type controls, reaching a 15% larger diaphyseal cross sectional area at 12 months of age. Mcpt4-/- mice also showed increased levels of a bone anabolic serum marker and higher periosteal bone formation rate. However, they were not protected from experimental osteoporosis, suggesting that chymase regulates normal bone homeostasis rather than the course of osteoporosis. Further, the absence of Mcpt4 resulted in age-dependent upregulation of numerous genes important for bone formation but no effects on osteoclast activity. In spite of the latter, Mcpt4-/- bones had increased cortical porosity and reduced endocortical mineralization. Mast cells were found periosteally and, notably, bone-proximal mast cells in Mcpt4-/- mice were degranulated to a larger extent than in wild type mice. Hence, chymase regulates degranulation of bone mast cells, which could affect the release of mast cell-derived factors influencing bone remodelling. Together, these findings reveal a functional impact of mast cell chymase on bone. Further studies exploring the possibility of using chymase inhibitors as a strategy to increase bone volume may be warranted.

[1]  M. Iglarz,et al.  Endothelin receptor antagonist macitentan or deletion of mouse mast cell protease 4 delays lesion development in atherosclerotic mice. , 2016, Life sciences.

[2]  M. MacDougall,et al.  Establishment of Immortalized BMP2/4 Double Knock‐Out Osteoblastic Cells Is Essential for Study of Osteoblast Growth, Differentiation, and Osteogenesis , 2015, Journal of cellular physiology.

[3]  G. Pejler,et al.  The Role of Mast Cells in Bacterial Infection. , 2016, American Journal of Pathology.

[4]  K. Michaëlsson,et al.  Osteoporosis: the emperor has no clothes , 2015, Journal of internal medicine.

[5]  M. Tsai,et al.  Approaches for analyzing the roles of mast cells and their proteases in vivo. , 2015, Advances in immunology.

[6]  L. Idolazzi,et al.  Bone involvement and osteoporosis in mastocytosis. , 2014, Immunology and allergy clinics of North America.

[7]  Piero Carninci,et al.  Redefinition of the human mast cell transcriptome by deep-CAGE sequencing. , 2014, Blood.

[8]  T. Vangansewinkel,et al.  Mast cells protect from post-traumatic spinal cord damage in mice by degrading inflammation-associated cytokines via mouse mast cell protease 4 , 2014, Neurobiology of Disease.

[9]  Susan M. Schlenner,et al.  Mast Cell Chymase Degrades the Alarmins Heat Shock Protein 70, Biglycan, HMGB1, and Interleukin-33 (IL-33) and Limits Danger-induced Inflammation* , 2013, The Journal of Biological Chemistry.

[10]  C. Cooper,et al.  Osteoporosis in the European Union: medical management, epidemiology and economic burden , 2013, Archives of Osteoporosis.

[11]  G. Pejler,et al.  Mast cell chymase modulates IL-33 levels and controls allergic sensitization in dust-mite induced airway inflammation , 2012, Mucosal Immunology.

[12]  D. Voehringer Protective and pathological roles of mast cells and basophils , 2013, Nature Reviews Immunology.

[13]  S. Hendrix,et al.  Mast cells protect from post‐traumatic brain inflammation by the mast cell‐specific chymase mouse mast cell protease‐4 , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[14]  E. Schwarz,et al.  PTH‐enhanced structural allograft healing is associated with decreased angiopoietin‐2–mediated arteriogenesis, mast cell accumulation, and fibrosis , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[15]  M. Amling,et al.  Increased osteoblast and osteoclast indices in individuals with systemic mastocytosis , 2013, Osteoporosis International.

[16]  G. Shi,et al.  Mast cell chymase and tryptase as targets for cardiovascular and metabolic diseases. , 2012, Current pharmaceutical design.

[17]  O. Hermine,et al.  Bone complications of mastocytosis: a link between clinical and biological characteristics. , 2013, The American journal of medicine.

[18]  H. Kluin-Nelemans,et al.  High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis , 2012, Allergy.

[19]  Microarray Profiling of Diaphyseal Bone of Rats Suffering from Hypervitaminosis A , 2012, Calcified Tissue International.

[20]  G. Passalacqua,et al.  Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis. , 2011, Bone.

[21]  T. Garland,et al.  Identification of quantitative trait loci influencing skeletal architecture in mice: Emergence of Cdh11 as a primary candidate gene regulating femoral morphology , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[22]  Z. Werb,et al.  Dual Targets for Mouse Mast Cell Protease-4 in Mediating Tissue Damage in Experimental Bullous Pemphigoid* , 2011, The Journal of Biological Chemistry.

[23]  J. Nyman,et al.  Differential effects between the loss of MMP‐2 and MMP‐9 on structural and tissue‐level properties of bone , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[24]  H. Melhus,et al.  High dietary intake of retinol leads to bone marrow hypoxia and diaphyseal endosteal mineralization in rats. , 2011, Bone.

[25]  T. V. van Berkel,et al.  Mast cell chymase inhibition reduces atherosclerotic plaque progression and improves plaque stability in ApoE-/- mice. , 2011, Cardiovascular research.

[26]  R. Civitelli,et al.  N-cadherin and cadherin 11 modulate postnatal bone growth and osteoblast differentiation by distinct mechanisms , 2010, Journal of Cell Science.

[27]  E. Daugas,et al.  Mouse Mast Cell Protease-4 Deteriorates Renal Function by Contributing to Inflammation and Fibrosis in Immune Complex-Mediated Glomerulonephritis , 2010, The Journal of Immunology.

[28]  Gunnar Pejler,et al.  Mast cell proteases: multifaceted regulators of inflammatory disease. , 2010, Blood.

[29]  W. Abraham,et al.  Dual inhibition of cathepsin G and chymase is effective in animal models of pulmonary inflammation. , 2010, American journal of respiratory and critical care medicine.

[30]  R. Turner,et al.  The Role of Mast Cells in Parathyroid Bone Disease , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[31]  F. Finkelman,et al.  Mast cells regulate homeostatic intestinal epithelial migration and barrier function by a chymase/Mcpt4-dependent mechanism , 2009, Proceedings of the National Academy of Sciences.

[32]  P. Libby,et al.  Critical Role of Mast Cell Chymase in Mouse Abdominal Aortic Aneurysm Formation , 2009, Circulation.

[33]  S. Khosla Increasing options for the treatment of osteoporosis. , 2009, New England Journal of Medicine.

[34]  S. Knight,et al.  Novel insights into the biological function of mast cell carboxypeptidase A. , 2009, Trends in immunology.

[35]  M. Åbrink,et al.  Mast cell chymase contributes to the antibody response and the severity of autoimmune arthritis , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[36]  L. Hellman,et al.  Serglycin proteoglycan is required for secretory granule integrity in mucosal mast cells. , 2007, The Biochemical journal.

[37]  S. Itohara,et al.  A Crucial Role for Matrix Metalloproteinase 2 in Osteocytic Canalicular Formation and Bone Metabolism* , 2006, Journal of Biological Chemistry.

[38]  B. Gruber,et al.  The role of mast cells in osteoporosis. , 2006, Seminars in arthritis and rheumatism.

[39]  J. Saffar,et al.  Time-course of mast cell accumulation in rat bone marrow after ovariectomy , 2001, Calcified Tissue International.

[40]  Y. Konttinen,et al.  Mast cells in atherosclerosis as a source of the cytokine RANKL , 2006, Clinical chemistry and laboratory medicine.

[41]  B. Premack,et al.  Proteolytic Activation of Alternative CCR1 Ligands in Inflammation1 , 2005, The Journal of Immunology.

[42]  M. Åbrink,et al.  A Key Role for Mast Cell Chymase in the Activation of Pro-matrix Metalloprotease-9 and Pro-matrix Metalloprotease-2* , 2005, Journal of Biological Chemistry.

[43]  F. Islam,et al.  Bone mass effects of a BMP4 gene polymorphism in postmenopausal women. , 2005, Bone.

[44]  D. Mooney,et al.  Bone regeneration in a rat cranial defect with delivery of PEI-condensed plasmid DNA encoding for bone morphogenetic protein-4 (BMP-4) , 2005, Gene Therapy.

[45]  Wei Zhao,et al.  Cytokine production by skin-derived mast cells: endogenous proteases are responsible for degradation of cytokines. , 2005, Journal of immunology.

[46]  M. Tsai,et al.  Mast cells as "tunable" effector and immunoregulatory cells: recent advances. , 2005, Annual review of immunology.

[47]  H. Chen,et al.  Ultrastructural changes in bones of the senescence-accelerated mouse (SAMP6): a murine model for senile osteoporosis. , 2004, Histology and histopathology.

[48]  S. Takai,et al.  A Specific Chymase Inhibitor, 2-(5-Formylamino-6-oxo-2-phenyl-1,6-dihydropyrimidine-1-yl)-N-[{3,4-dioxo-1-phenyl-7-(2-pyridyloxy)}-2-heptyl]acetamide (NK3201), Suppresses Development of Abdominal Aortic Aneurysm in Hamsters , 2004, Journal of Pharmacology and Experimental Therapeutics.

[49]  M. Åbrink,et al.  The Chymase, Mouse Mast Cell Protease 4, Constitutes the Major Chymotrypsin-like Activity in Peritoneum and Ear Tissue. A Role for Mouse Mast Cell Protease 4 in Thrombin Regulation and Fibronectin Turnover , 2003, The Journal of experimental medicine.

[50]  K. Arakawa,et al.  Chymase Inhibitor Improves Survival in Hamsters with Myocardial Infarction , 2003, Journal of cardiovascular pharmacology.

[51]  S. Takai,et al.  Oral administration of a novel chymase inhibitor, NK3201, prevents peritoneal adhesion formation in hamsters. , 2002, Japanese journal of pharmacology.

[52]  M. Miyazaki,et al.  Therapeutic potential of a specific chymase inhibitor in atopic dermatitis. , 2002, Japanese journal of pharmacology.

[53]  L. Thompson,et al.  Mast cell involvement in fibrodysplasia ossificans progressiva. , 2001, Human pathology.

[54]  B. Julian,et al.  Expression of stem cell factor by osteoblasts in normal and hyperparathyroid bone: relation to ectopic mast cell differentiation , 1999, Virchows Archiv.

[55]  G. Andersson,et al.  Comparative studies of rat recombinant purple acid phosphatase and bone tartrate-resistant acid phosphatase. , 1997, The Biochemical journal.

[56]  H. Neurath,et al.  Mast cell proteases. , 1981, Methods in enzymology.

[57]  E. Storey,et al.  LOW‐CALCIUM/HIGH PHOSPHORUS RICKETS IN RATS. I. MAST CELL CHANGES , 1979, Pathology.